Dexcom DXCM
Dexcom Q3 FY24: revenue $994.2M; diluted EPS $0.34
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001093557-24-000180
- Document
- 10-Q
Key figures from this report
These are the numbers Dexcom reported for Q3 FY24, the quarter ended Sep 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$994.2MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Net income$134.6MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS$0.34No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$621.2MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations$199.5MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.
- GE HealthCare Technologies GEHC public float $34.0B, Jun 30, 2025
- Resmed RMD public float $34.9B, Dec 31, 2025
- Edwards Lifesciences EW public float $45.9B, Jun 30, 2025
- STERIS STE public float $24.2B, Sep 30, 2025
- Insulet PODD public float $22.1B, Jun 30, 2025